PURPOSE: Long-term administration of adjuvant temozolomide is common practice in many institutions, especially when treatment is well tolerated and stable disease is achieved. In this study, we evaluate the feasibility and efficacy of long-term temozolomide in patients with glioblastoma multiforme treated at a single institution. METHODS: One hundred and fourteen patients with newly diagnosed glioblastoma were followed for the course of their disease. Treatment consisted of surgery [gross total resection (GTR) subtotal resection (STR) or biopsy] followed by radiotherapy and concomitant temozolomide. Adjuvant temozolomide was administered until evidence for progressive disease or serious side effects occurred. Follow-up was routinely performed every 3 months. RESULTS: One hundred and fourteen patients with glioblastoma multiforme received a median of 6 cycles of adjuvant first-line temozolomide (range 1-57). For patients with less than 6 cycles, chemotherapy was stopped in 60% for reasons other than progression, while only in 17% of patients receiving 6 or more (P < 0.0001). Median TTP was 7 months (95% CI: 6-10 months). PFS after 6 months was 53%. Median OS in all patients was 15 months (95% CI: 13-18 months). TTP and OS directly correlate with the amount of chemotherapy cycles (each P < 0.0001). No significant influence of the extent of surgical treatment on PFS (P = 0.2141) and OS (P = 0.4308) could be detected. CONCLUSION: This data set suggests that long-term administration of temozolomide is safe and efficacious. Side effects occur more frequently in the early phase of drug administration (<6 cycles). There is a strong correlation of long-term temozolomide on PFS and OS regardless of the extent of surgery and other factors.
PURPOSE: Long-term administration of adjuvant temozolomide is common practice in many institutions, especially when treatment is well tolerated and stable disease is achieved. In this study, we evaluate the feasibility and efficacy of long-term temozolomide in patients with glioblastoma multiforme treated at a single institution. METHODS: One hundred and fourteen patients with newly diagnosed glioblastoma were followed for the course of their disease. Treatment consisted of surgery [gross total resection (GTR) subtotal resection (STR) or biopsy] followed by radiotherapy and concomitant temozolomide. Adjuvant temozolomide was administered until evidence for progressive disease or serious side effects occurred. Follow-up was routinely performed every 3 months. RESULTS: One hundred and fourteen patients with glioblastoma multiforme received a median of 6 cycles of adjuvant first-line temozolomide (range 1-57). For patients with less than 6 cycles, chemotherapy was stopped in 60% for reasons other than progression, while only in 17% of patients receiving 6 or more (P < 0.0001). Median TTP was 7 months (95% CI: 6-10 months). PFS after 6 months was 53%. Median OS in all patients was 15 months (95% CI: 13-18 months). TTP and OS directly correlate with the amount of chemotherapy cycles (each P < 0.0001). No significant influence of the extent of surgical treatment on PFS (P = 0.2141) and OS (P = 0.4308) could be detected. CONCLUSION: This data set suggests that long-term administration of temozolomide is safe and efficacious. Side effects occur more frequently in the early phase of drug administration (<6 cycles). There is a strong correlation of long-term temozolomide on PFS and OS regardless of the extent of surgery and other factors.
Authors: P Hau; D Koch; T Hundsberger; E Marg; B Bauer; R Rudolph; M Rauch; A Brenner; P Rieckmann; J Schuth; T Jauch; H Koch; U Bogdahn Journal: Neurology Date: 2007-02-27 Impact factor: 9.910
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin Journal: Semin Radiat Oncol Date: 2003-07 Impact factor: 5.934
Authors: Marco Skardelly; Elena Dangel; Julia Gohde; Susan Noell; Felix Behling; Guilherme Lepski; Christian Borchers; Marilin Koch; Jens Schittenhelm; Sotirios Bisdas; Aline Naumann; Frank Paulsen; Daniel Zips; Ulrike von Hehn; Rainer Ritz; Marcos Soares Tatagiba; Ghazaleh Tabatabai Journal: Oncologist Date: 2017-03-30
Authors: Daniel Ruiz-Sánchez; Miguel Alaguero Calero; Alejandro José Sastre-Heres; María Teresa Iglesias García; Miguel Angel Calleja Hernandez; Fernando Martínez Martinez; Jaime Peña-Díaz Journal: Oncol Lett Date: 2012-08-14 Impact factor: 2.967
Authors: Alia M Attia; Hanan A Eltybe; Mayada F Sedik; Ahmed Mubarak Hefni; Marwa I Abdelgawad; Ashraf Farrag; Abdelhakeem A Essa; Mohamed M El-Barody; Noha M Attia Journal: Am J Cancer Res Date: 2022-01-15 Impact factor: 6.166
Authors: M W Pitz; M Lipson; B Hosseini; P Lambert; K Guilbert; D Lister; G Schroeder; K Jones; C Mihalicioiu; D D Eisenstat Journal: Curr Oncol Date: 2012-12 Impact factor: 3.677